Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A L Ho

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2018
Developing androgen receptor targeting for salivary gland cancersA L Ho
Bulletin - N. Z. Society of Periodontology|February 1, 1976
Thoughts on preventive dentistryA L Ho
The British Journal of Dermatology|January 30, 2019
Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practiceB Y Yan, B P Hibler, T Menge, et al.
Neuro-Chirurgie|January 24, 2021
CSF Otorrhea: A rare presentation of spinal myxopapillary ependymomaA Y Feng, M C Jin, S Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2016
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinomaA L Ho, L Dunn, E J Sherman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2018
Developing androgen receptor targeting for salivary gland cancersA L Ho
Bulletin - N. Z. Society of Periodontology|February 1, 1976
Thoughts on preventive dentistryA L Ho
The British Journal of Dermatology|January 30, 2019
Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practiceB Y Yan, B P Hibler, T Menge, et al.
Neuro-Chirurgie|January 24, 2021
CSF Otorrhea: A rare presentation of spinal myxopapillary ependymomaA Y Feng, M C Jin, S Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)L A Dunn, M G Fury, H Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2016
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinomaA L Ho, L Dunn, E J Sherman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)A Drilon, G Li, S Dogan, et al.
Pageof 1